🏛️ Verified NIH Record • Updated 2026-02-02
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission (NCT03059485)
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Beth Israel Deaconess Medical Center
🩺 Plain-English Summary (8th-Grade Level)
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myelogenous Leukemia
- Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia — Los Angeles, California
- Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients — Boston, Massachusetts
- Allo HSCT Using RIC and PTCy for Hematological Diseases — Minneapolis, Minnesota
- ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Cleveland, Ohio
- Cord Blood Transplantation in Children and Young Adults With Blood Cancer — New York, New York
Explore by condition: All Acute Myelogenous Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.